BridgeBio to present Phase 3 infigratinib trial data at ICCBH 2026

June 22, 2026 7:30 AM

BridgeBio Pharma (Nasdaq: BBIO) announced it will present primary results from its Phase 3 PROPEL 3 trial of oral infigratinib ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found